Kyverna Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Kyverna Therapeutics, Inc. (KYTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 103.22 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-11
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 96.38K shares, a 34.09% decline year-over-year.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 6.84K shares, a 86.05% decline year-over-year.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 47.82K shares, a 6110.39% increase year-over-year.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 162.09K shares.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 405.19K shares, a 8339.80% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 4.80K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 96.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 103.22K shares 10-Q · filed 2026-08-11 | 151.04K shares derived: sum of 3 quarters · filed 2026-08-11 | 313.13K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 6.84K shares 10-Q · filed 2026-05-12 | 54.66K shares derived: sum of 2 quarters · filed 2026-05-12 | 216.75K shares derived: sum of 3 quarters · filed 2026-05-12 | 362.97K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 47.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 209.91K shares derived: sum of 2 quarters · filed 2026-03-26 | 356.13K shares derived: sum of 3 quarters · filed 2026-03-26 | 405.19K shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 162.09K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 308.31K shares derived: sum of 2 quarters · filed 2025-11-12 | 357.38K shares 10-Q · filed 2025-11-12 | 358.14K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 146.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 195.28K shares 10-Q · filed 2025-08-12 | 196.05K shares derived: sum of 3 quarters · filed 2025-08-12 | |
| 2025-03-31 | 49.07K shares 10-Q · filed 2025-05-13 | 49.84K shares derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2024-12-31 | 770.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 4.80K shares 10-K · filed 2025-03-27 | ||
| 2024-09-30 | 4.03K shares 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |